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Introduction
The conditioned avoidance response (CAR) and phency-
clidine (PCP)-induced hyperlocomotion are two widely 
used animal models for the study of antipsychotic drugs. 
Both models have high predictive validity for antipsy-
chotic efficacy, as all clinically approved anti psychotics 
[e.g. haloperidol (HAL), olanzapine (OLZ), and risperi-
done]. but not other classes of psychotherapeutic drugs 
(e.g. anxiolytics, antidepressants), selectively disrupt 
avoidance responding, and inhibit the PCP-induced in-
crease in motor activity upon acute administration (Glea-
son and Shannon, 1997; Li et al., 2004b). More importantly, 
both models are capable of capturing the time course of 
antipsychotic treatment in the clinic. With repeated drug 
administration, anti psychotics progressively enhance 
their disruption of avoidance responding (Li et al., 2009a, 
2009b, 2010; Mead and Li, 2010) and their inhibition of 
PCP-induced hyperlocomotion over the drug treatment 
period (Sun et al., 2009). This progressive increase in an-
tipsychotic  effects due to repeated drug administration is 
termed as antipsychotic sensitization. This behavioral pat-
tern is consistent with clinical observations showing that 
antipsychotic action increases in magnitude with repeated 
treatment over time (Agid et al., 2003, 2006; Kapur et al., 
2005; Leucht et al., 2005; Emsley et al., 2006; Glick et al., 
2006; Raedler et al., 2007). 
In comparison with extensive research on behavioral 
sensitization induced by psychotomimetic drugs (e.g. am-
phetamine, cocaine, PCP, etc.; Robinson and Becker, 1986; 
Pierce and Kalivas, 1997), antipsychotic sensitization, es-
pecially the type induced by atypical antipsychotics (e.g. 
OLZ, clozapine, risperidone) is relatively new and less 
well understood. This situation is peculiar, given the 
fact that anti psychotics, such as drugs of abuse, are of-
ten taken repeatedly by people for a prolonged period of 
time, and antipsychotic sensitization is thought to be an 
important mechanism supporting the maintenance of the 
antipsychotic effect (Li et al., 2007). Thus, antipsychotic 
sensitization should have received more attention than it 
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Abstract 
Repeated administration of haloperidol (HAL) and olanzapine (OLZ) causes a progressively enhanced disruption of the conditioned avoid-
ance response (CAR) and a progressively enhanced inhibition of phencyclidine (PCP)-induced hyperlocomotion in rats (termed antipsychotic 
sensitization). Both actions are thought to reflect intrinsic antipsychotic activity. The present study examined the extent to which antipsy-
chotic-induced sensitization in one model (e.g. CAR) can be transferred or maintained in another (e.g. PCP hyperlocomotion) as a means of 
investigating the contextual and behavioral controls of antipsychotic sensitization. Well-trained male Sprague-Dawley rats were first repeat-
edly tested in the CAR or the PCP (3.2 mg/kg, subcutaneously) hyperlocomotion model under HAL or OLZ for 5 consecutive days. Then they 
were switched to the other model and tested for the expression of sensitization. Finally, all rats were switched back to the original model and 
retested for the expression of sensitization. Repeated HAL or OLZ treatment progressively disrupted avoidance responding and decreased 
PCP-induced hyperlocomotion, indicating a robust sensitization. When tested in a different model, rats previously treated with HAL or OLZ 
did not show a stronger inhibition of CAR-induced or PCP-induced hyperlocomotion than those treated with these drugs for the first time; 
however, they did show such an effect when tested in the original model in which they received repeated antipsychotic treatment. These find-
ings suggest that the expression of antipsychotic sensitization is strongly influenced by the testing environment and/or selected behavioral re-
sponse under certain experimental conditions. Distinct contextual cues and behavioral responses may develop an association with uncondi-
tional drug effects through a Pavlovian conditioning process. They may also serve as occasion setters to modulate the expression of sensitized 
responses. As antipsychotic sensitization mimics the clinical effects of antipsychotic treatment, understanding the neurobiological mechanisms 
of antipsychotic sensitization and its contextual control would greatly enhance our understanding of the psychological and neurochemical na-
ture of antipsychotic treatment in the clinic.  
Keywords: behavioral sensitization, conditioned avoidance response, haloperidol, olanzapine, phencyclidine, rat, time course of antipsychotic 
effect   
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currently has. One major issue that may have contributed 
to this lack of attention is the difficulty in demonstrating 
its existence. For example, in studies using the prepulse 
inhibition paradigm, behavioral sensitization has never 
been consistently established among different antipsy-
chotics (Geyer et al., 2001; Li et al., 2011a). 
As repeated antipsychotic treatment induces sensitiza-
tion in both the CAR and the PCP hyperlocomotion mod-
els, and both sensitizations putatively reflect the same 
antipsychotic activity over time, one interesting and crit-
ically important question is whether antipsychotic-in-
duced sensitization is situation specific. In other words, 
could the antipsychotic-induced sensitization in one 
model (e.g. CAR) be transferred or maintained in another 
model (e.g. PCP hyperlocomotion)? We postulated that 
studying across-model transfer of antipsychotic sensiti-
zation would allow us to investigate the contextual and 
behavioral controls of antipsychotic sensitization. If anti-
psychotic sensitization results from inevitable neurobio-
logical adaptations produced by the direct pharmacolog-
ical actions of the drug (Tarsy and Baldessarini, 1974), it 
should be transferrable across models and suggests that 
contextual and behavioral variables have little influence 
on the development of antipsychotic sensitization. In con-
trast, if the context and the behaviors associated with 
drug administration have a powerful control on the ex-
pression of antipsychotic sensitization, it should not be 
transferrable between models. 
The present study addressed this question. We tested 
HAL and OLZ, two representative drugs for typical and 
atypical antipsychotics, and examined bidirectional trans-
fer between the CAR and the PCP models. Our general 
approach was to induce behavioral sensitization in one 
model through repeated drug administration, then to test 
its expression in another model, and finally to retest its 
expression back in the first model. Our results showed 
that HAL and OLZ sensitization in both models only 
manifested itself when the induction condition was the 
same as the test condition. These results are in general 
agreement with research on psychomotor sensitization, 
which also shows that the expression of behavioral sen-
sitization is greatly impacted by contextual cues (Vezina 
and Stewart, 1984; Anagnostaras and Robinson, 1996; 
Robinson et al., 1998) and selected behavior responses 
(Ohmori et al., 2000).  
Methods
Subjects 
Adult male Sprague-Dawley rats (226-250 g upon arrival, 
Charles River, Portage, Michigan, USA) were used. They 
were housed two per cage in 48.3 × 26.7 × 20.3-cm trans-
parent polycarbonate cages under 12-h light/dark con-
ditions (light on between 6:30 a.m. and 6:30 p.m.). Room 
temperature was maintained at 22 ± 1°C with a  relative 
humidity of 45-60%. Food and water were freely avail-
able. Subjects were allowed at least 1 week of habitua-
tion to the animal facility before being used in experi-
ments. All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of 
Nebraska-Lincoln. 
Drugs and choice of doses 
The injection solution of HAL (5.0 mg/ml ampoules; 
Shanghai Xudong Haipu Pharmaceutical Co., Ltd, Shang-
hai, China) was obtained by mixing the stock with ster-
ile water. OLZ (a gift from the National Institute of Men-
tal Health Drug Supply Program) was dissolved in 1.0% 
glacial acetic acid in distilled water. PCP hydrochloride 
(a gift from the National Institute of Drug Administration 
Chemical Synthesis and Drug Supply Program) was dis-
solved in 0.9% saline. All drugs were administered sub-
cutaneously. In the first two experiments (from CAR to 
PCP), we tested three doses of HAL (0.03, 0.05, and 0.10 
mg/kg) and OLZ (0.5, 1.0, and 2.0 mg/kg). At these 
doses, HAL and OLZ produced a comparable level of dis-
ruption on avoidance responding, which is considered a 
validated behavioral index of antipsychotic action (Li et 
al., 2004a, 2007, 2009a, 2009b; Mead and Li, 2010). Further-
more, both drugs at these doses give rise to 50-80% stria-
tal dopamine D2 occupancy in rats, which is comparable 
with values observed in schizophrenic patients (Kapur et 
al., 2005). On the basis of the findings from the first two 
experiments and our published work (Sun et al., 2009), we 
tested HAL at 0.05 mg/kg and OLZ at 1.0 mg/kg in the 
last two experiments (from PCP to CAR) because they in-
duce a robust sensitization effect in the PCP hyperloco-
motion model (Sun et al.., 2009). 
Two-way avoidance conditioning apparatus 
Eight identical two-way shuttle boxes custom designed 
and manufactured by Med Associates (St. Albans, Ver-
mont, USA) were used. Each box was housed in a ven-
tilated, sound-insulated isolation cubicle (96.52-cm width 
× 35.56-cm diameter × 63.5-cm height). Each box was 64-
cm long, 30-cm high (from grid floor), and 24-cm wide, 
and was divided into two equal-sized compartments 
by a partition with an arch-style doorway (15-cm high 
x 9-cm wide at base). A barrier (4-cm high) was placed 
between the two compartments, so the rats had to jump 
from one compartment to the other. The grid floor con-
sisted of 40 stainless-steel rods with a diameter of 0.48 
cm, spaced 1.6 cm apart center to center, through which 
a scrambled foot shock [unconditioned stimulus (US), 
0.8 mA, maximum duration: 5 s] was delivered by a con-
stant current shock generator (Model ENV-410B) and 
scrambler (Model ENV-412). The rat’s location and cross-
ings between compartments were monitored by a set of 
16 photobeams (ENV-256-8P) affixed at the bottom of the 
box (3.5 cm above the grid floor). Illumination was pro-
vided by two house lights mounted  at the top of each 
compartment. The conditioned stimulus (CS; i.e., 76 dB 
white noise) was produced by a speaker (ENV 224 AMX) 
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mounted on the ceiling of the cubicle, centered above the 
shuttle box. Background noise (approximately 74 dB) was 
provided by a ventilation fan affixed at the top corner of 
each isolation cubicle. All training and testing procedures 
were controlled by Med Associates programs running on 
a computer. 
Motor activity monitoring apparatus 
Sixteen activity boxes were housed in a quiet room. The 
boxes were 48.3 × 26.7 × 20.3-cm transparent polycarbon-
ate cages, which were similar to the home cages, but were 
each equipped with a row of six photocell beams (7.8 cm 
between adjacent beams) placed 3.2 cm above the floor of 
the cage. A computer detected the disruption of the pho-
tocell beams and recorded the number of beam breaks. All 
experiments were run during the light cycle.  
Experiment 1: Transferability of haloperidol-induced sen-
sitization from the conditioned avoidance response model 
to the phencyclidine hyperlocomotion model 
This experiment examined whether the sensitization ef-
fect induced by repeated HAL treatment in the CAR 
model was transferrable to the PCP-induced hyperloco-
motion model. The experiment comprised the following 
three phases: avoidance training/sensitization induction 
in the CAR, sensitization assessment in the PCP hyper-
locomotion model, and sensitization reassessment in the 
CAR model. 
Avoidance training/sensitization induction in the conditioned avoid-
ance response: Seventy-two rats (run in two batches) were 
first habituated to the CAR boxes for 2 days (20 min/day). 
Then, they were trained for conditioned avoidance re-
sponding for 10 sessions over a 2-week period. Each ses-
sion consisted of 30 trials. Every trial started by present-
ing a white noise (CS) for 10 s, followed by a continuous 
scrambled foot shock [0.8 mA, US, maximum duration = 5 
s] on the grid floor. If a rat moved from one compartment 
into the other within the 10s of CS presentation, it avoided 
the shock and this shuttling response was recorded as 
avoidance. If the rat remained in the same compartment 
for more than 10s and made a crossing upon receiving the 
foot shock, this response was recorded as escape. If the rat 
did not respond during the entire 5-s presentation of the 
shock, the trial was terminated and escape failure was re-
corded. The total number of avoidance responses was re-
corded for each session. Intertrial intervals varied ran-
domly between 30 and 60 s. 
At the end of the training session, 59 rats reached the 
training criterion ( > 70% avoidance in each of the last 
two sessions). They were first matched on avoidance per-
formance on the last training day (i.e., predrug) to cre-
ate blocks of rats (n = 3–4 rats/block) that were approx-
imately equal in performance. Within each block, they 
were then randomly assigned to one of four groups: 
HAL, 0.03 mg/kg (HAL 0.03, n = 7); HAL, 0.05 mg/kg 
(HAL 0.05, n = 7); HAL, 0.10 mg/kg (HAL 0.10, n= 7); and 
vehicle (VEH, n = 38), and tested daily under the CS-only 
(no shock, 30 trials/daily sessions) condition for 5 consec-
utive days. The CS-only condition was used to control the 
possible confound of the number of shocks received and 
to exclude any possible relearning effect caused by the 
presence of the US. During each drug test, rats were first 
injected with HAL or sterile water. One hour later, they 
were placed in the CAR boxes and tested. Because of an 
error in data collection, data for seven rats were lost (five 
VEH rats, one HAL 0.05, and one HAL 0.10). Thus, the fi-
nal numbers of rats entered into the subsequent drug test-
ing were as follows: HAL 0.03 (n = 7), HAL 0.05 (n = 6), 
HAL 0.10 (n = 6), and VEH (n = 33). 
Sensitization assessment in the phencyclidine hyperlocomotion 
model: One day after the CAR drug testing, rats were ha-
bituated to the motor activity testing boxes for 30 min. On 
day 2, rats that were previously treated with HAL in the 
CAR received the same HAL treatment, followed by PCP 
(termed HAL-HAL 0.03 + PCP, HAL-HAL 0.05 + PCP, and 
HAL-HAL 0.10 + PCP groups). Rats that were previously 
treated with sterile water in the CAR were randomly as-
signed to five groups: three groups received HAL, fol-
lowed by PCP (termed VEH-HAL 0.03 + PCP, n = 5; VEH-
HAL 0.05 + PCP, n = 6; and VEH-HAL 0.10 + PCP, n = 5), 
and two groups received sterile water, followed by PCP or 
saline (termed VEH-VEH + PCP, n = 8 and VEH-VEH + 
VEH, n = 9). During this test, rats were first injected with 
HAL or sterile water. Immediately after injection, they 
were placed in the motor activity testing boxes for 30 min. 
At the end of the 30-min period, rats were taken out and 
injected with either VEH (0.9% saline) or PCP (1.6 mg/kg, 
subcutaneously) and placed back in the boxes for another 
60 min (Sun et al., 2009). Motor activity (number of photo-
beam breaks) was measured at 5-min intervals throughout 
the entire 90-min testing session. 
Sensitization reassessment in the conditioned avoidance response: 
One day after the PCP hyperlocomotion test, all rats were 
returned back to the CAR task and tested drug-free for 
one session under the CS-only (no shock) condition and 
retrained for one session under the CS-US condition to 
bring their avoidance back to the predrug level. A final 
challenge test for sensitization was conducted 24 h after 
the retraining session, during which all rats were injected 
with HAL 0.03 and tested for avoidance performance in 
the CS-only condition (30 trials) 1 h later. Table 1 presents 
the group information in different phases of Experiment 1. 
Experiment 2: Transferability of olanzapine-induced sen-
sitization from the conditioned avoidance response model 
to the phencyclidine hyperlocomotion model 
This experiment examined whether the sensitization in-
duced by repeated OLZ treatment in the CAR model was 
transferrable to the PCP hyperlocomotion model. The basic 
procedure was identical to that of Experiment 1, with the 
exception that HAL (0.03, 0.05, and 1.0 mg/kg) was 































replaced by OLZ (0.5, 1.0, and 2.0 mg/kg). Seventy-two 
rats (run in two batches) were used, of which 58 reached 
the learning criterion. They were then randomly assigned 
to one of the following four groups in the initial CAR test 
phase: OLZ 0.5 mg/kg (OLZ 0.5, n = 7), OLZ 1.0 mg/kg 
(OLZ 1.0, n = 7), OLZ 2.0 mg/kg (OLZ 2.0, n = 7), and 
VEH (n = 37). At the end of the CAR testing phase, data 
for five rats were lost (two VEH rats, two OLZ 1.0, and 
one OLZ 2.0). Thus, the final numbers for each group en-
tered in the subsequent drug testing were: OLZ 0.5: n = 
7; OLZ 1.0: n = 5; OLZ 2.0: n = 6; and VEH: n = 35. In the 
PCP hyperlocomotion test phase, the VEH groups were 
split into five groups: VEH-OLZ 0.5 + PCP (n = 7), VEH-
OLZ 1.0 + PCP (n = 6), VEH-OLZ 2.0 + PCP (n = 7), VEH-
VEH + PCP (n = 7), and VEH-VEH + VEH (n = 8). In the 
final sensitization reassessment test, all of the rats were 
injected with OLZ 0.5. Table 2 depicts the group informa-
tion in different phases of Experiment 2. 
Experiment 3: Transferability of haloperidol-induced sen-
sitization from the phencyclidine hyperlocomotion model 
to the conditioned avoidance response model 
This experiment was a mirror experiment to Experiment 
1 in the sense that it examined the opposite direction of 
sensitization transfer. We examined whether the sensi-
tization-like effect induced by repeated HAL (0.05 mg/
kg, subcutaneously) treatment in the PCP hyperlocomo-
tion  model is transferrable to the CAR model. HAL 0.05 
was tested because this dose produces a reliable sensitiza-
tion effect (see Experiment 1 and Li et al., 2010). The entire 
experiment comprised the following three phases: sen-
sitization induction in the PCP hyperlocomotion model, 
sensitization assessment in the CAR, and sensitization re-
assessment in the PCP hyperlocomotion model. 
Sensitization induction in the phencyclidine hyperlocomotion mode/. 
Thirty-two rats were first handled and habituated to the 
avoidance conditioning apparatus for 2 days (30 min/
day) and then trained for 10 consecutive days to acquire 
robust conditioned avoidance responding. At the end of 
the training phase, 25 rats that had reached the training 
criterion were used in the subsequent tests. They were 
randomly assigned to the following two groups: HAL 
0.05 (n = 8) and VEH (n = 17) groups. On day 1, rats were 
habituated in the motor activity boxes for 30 min. On day 
2, rats were first injected with HAL (0.05 mg/kg) or VEH 
(sterile water) and then immediately placed in the boxes 
for 30 min. At the end of the 30-min period, they were 
taken out and injected with PCP (3.2 mg/kg) and placed 
back in the boxes for another 60 min. This procedure was 
repeated for another 4 days (a total of 5 testing days). Our 
previous work shows that repeated antipsychotic treat-
ment (e.g. HAL, clozapine, OLZ, etc.) produces a robust 
sensitization effect in this PCP model (Sun et al., 2009). 
Sensitization assessment in the conditioned avoidance response: One 
day after the last (fifth) PCP hyperlocomotion test, all rats 
were given a CAR retraining session to bring their avoid-
ance back to the predrug level. One day later, the sensiti-
zation assessment test was conducted. During this test, rats 
in the VEH group were randomly assigned to two sub-
groups: VEH-VEH (n = 9) and VEH-HAL 0.03 (n = 8) and 
received an injection of sterile water or HAL 0.03, respec-
tively. Rats in the HAL 0.05 group were injected with HAL 
0.03 (termed HAL 0.05-HAL 0.03 group). They were then 
tested for avoidance performance under the CS-only con-
dition (no shock) for 30 trials 1 h after injection. 
Sensitization reassessment in the phencyclidine hyperlocomotion 
model. One day after the sensitization test in the CAR, a 
final sensitization reassessment test was conducted back 
in the PCP locomotor model. All rats were first injected 
with HAL 0.03 and then immediately placed in the mo-
tor activity boxes for 30 min. At the end of the 30-min pe-
riod, rats were taken out and injected with PCP (3.2 mg/
kg) and placed back in the boxes for another 60 min. Mo-
tor activity was measured at 5-min intervals throughout 
the entire 90-min testing session. 
Experiment 4: Transferability of olanzapine-induced 
sensitization from the phencyclidine hyperlocomotion 
model to the conditioned avoidance response model 
This experiment was a mirror experiment to Experiment 2. 
It followed the same procedure as Experiment 3, with the 
Table 1. A schematic depiction of the experimental groups formed 
at different phases of Experiment 1. 
   CAR     Locomotor activity     CAR 
4 groups            8 groups    4 groups 
 VEH-VEH + VEH (n=9)
 VEH-VEH + PCP (n=8) 
VEH (n=33)  VEH-HAL 0.03 + PCP (n=5)  VEH-HAL 0.03 
 VEH-HAL 0.05 + PCP (n=6) 
 VEH-HAL 0.10 + PCP (n=5) 
HAL 0.03 (n=7)  HAL 0.03-HAL 0.03 + PCP HAL 0.03-HAL 0.03 
HAL 0.05 (n=6)  HAL 0.05-HAL 0.05 + PCP HAL 0.05-HAL 0.03 
HAL 0.10 (n=6)  HAL 0.10-HAL 0.10 + PCP HAL 0.10-HAL 0.03 
Letters in bold indicate the type of treatments administered at different 
phases. CAR, conditioned avoidance response; HAL, haloperidol; PCP, phen-
cyclidine; VEH, vehicle. 
Table 2. A schematic depiction of the experimental groups formed 
at different phases of Experiment 2. 
   CAR     Locomotor activity     CAR 
4 groups            8 groups    4 groups 
 VEH-VEH + VEH (n=8) 
 VEH-VEH + PCP (n=7) 
VEH (n=35)  VEH-OLZ 0.5 + PCP (n=7)  VEH-OLZ 0.5 
 VEH-OLZ 1.0 + PCP (n=6) 
 VEH-OLZ 2.0 +  PCP (n=7) 
OLZ 0.5 (n=7)  OLZ 0.5-OLZ 0.5 + PCP  OLZ 0.5-OLZ 0.5 
OLZ 1.0 (n=5)  OLZ 1.0-OLZ 1.0 + PCP  OLZ 1.0-OLZ 0.5 
OLZ 2.0 (n=6)  OLZ 2.0-OLZ 2.0 + PCP  OLZ 2.0-OLZ 0.5 
Letters in bold indicate the type of treatments administered at different 
phases. CAR, conditioned avoidance response; OLZ, olanzapine; PCP. phen-
cyclidine; VEH, vehicle.  
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exception that HAL (0.05 mg/kg) was replaced by OLZ 
(1.0 mg/kg). Thirty-two rats were used, of which 26 rats 
reached the training criterion. They were then randomly 
assigned to OLZ 1.0 (n = 9) and VEH (n = 17) and tested 
in the PCP hyperlocomotion model for 5 days. During the 
CAR test phase, the VEH group was randomly split into 
two groups: VEH-VEH (n = 8) and VEH-OLZ 0.5 (n = 9), 
and received an injection of sterile water or OLZ 0.5, re-
spectively. Rats in the OLZ 1.0 group received OLZ 0.5. In 
the sensitization reassessment test, all rats were adminis-
tered OLZ 0.5, followed by PCP 3.2 30 min later. 
Statistical analysis 
All data were expressed as mean ± standard error of 
the mean. Data from the five drug testing sessions (e.g., 
avoidance response and PCP-induced motor activity) 
were analyzed using a factorial repeated-measures anal-
ysis of variance (ANOVA), with the between-subjects 
factor being drug group and the within-subjects factor 
being test session. One-way ANOVAs, followed by post-
hoc Tukey honestly significant difference tests (for > 3 
groups) were used to identify group differences on a spe-
cific testing session. For a two-group comparison, inde-
pendent-samples t-tests were used. A conventional two-
tailed level of significance at the 5% level was required. 
Results
Experiment 1: Transferability of haloperidol-induced 
sensitization from the conditioned avoidance response 
model to the phencyclidine hyperlocomotion model 
Repeated haloperidol treatment produced a progressively 
enhanced disruption of avoidance responding in a dose-
dependent manner 
Figure 1a shows the number of avoidance responses 
made by the rats in the four groups during the five drug 
sessions. The three HAL groups showed a progressive 
across-session decrease in avoidance responding. The 
VEH group maintained a high level of avoidance re-
sponding throughout this phase. Repeated-measures 
ANOVA revealed a significant main effect of group [F(3, 
48) = 49.20, P < 0.001] and session [F(4, 192) = 11.64, P< 
0.001], and a significant group × session interaction 
[F(12, 192) = 3.06, P < 0.001]. Post-hoc tests revealed that 
all three HAL groups were significantly different from 
the VEH group (all P < 0.001). In addition, the HAL 0.10 
group differed significantly from the HAL 0.03 group (P 
< 0.001) but not from the HAL 0.05 group. 
Haloperidol sensitization did not transfer to the phency-
clidine hyperlocomotion model 
Figure 1b shows the mean motor activity of the eight 
groups of rats during the 60-min test period after saline 
or PCP injection. One-way ANOVA revealed a significant 
main effect of group [F(7,44) = 4.40, P < 0.001]. Post-hoc 
Tukey tests showed that in comparison with the VEH-
VEH + VEH group, the VEH-VEH + PCP group had a 
significantly higher motor activity (P < 0.001). This PCP 
effect was attenuated by HAL pretreatment. In compar-
ison with the VEH-VEH + PCP group, all except HAL 
0.10-HAL 0.10 + PCP and VEH-HAL 0.05 + PCP had sig-
nificantly lower motor activity; all P values were less than 
0.05. More importantly, when the pairs of acute and re-
peated HAL groups were compared (e.g., VEH-HAL 0.05 
+ PCP vs. HAL 0.05-HAL 0.05 + PCP), no significant dif-
ference was found. 
Haloperidol sensitization was detected in the conditioned 
avoidance response model and showed a dose-dependent 
function 
Figure 1c shows the number of avoidance responses dur-
ing the CS-only, retraining, and sensitization reassess-
ment sessions in the CAR model. In the CS-only session, 
HAL 0.03 and HAL 0.05 groups still differed significantly 
from the VEH and HAL 0.10 group, [F(3,48) = 8.68, P < 
0.001], post-hoc tests with all P values of less than 0.05. 
These differences disappeared in the retraining session 
[F(3, 48) = 0.14, not significant (NS)]. In the sensitization 
reassessment test, all rats were tested under HAL 0.03. 
One-way ANOVA showed a significant effect of group 
[F(3, 48) = 7.77, P < 0.001]. Post-hoc tests showed that the 
HAL 0.10 and HAL 0.05 groups had significantly fewer 
avoidances than the VEH group (P < 0.02 and 0.001, re-
spectively), which did not differ significantly from the 
HAL 0.03 group. 
Experiment 2: transferability of olanzapine-induced 
sensitization from the conditioned avoidance response 
model to the phencyclidine hyperlocomotion model 
Repeated olanzapine treatment produced a progressively 
enhanced disruption of avoidance responding in a dose-
dependent manner 
Figure 2a shows the number of avoidance responses 
made by the rats in the four groups during the five drug 
sessions. The three OLZ groups showed a progressive 
across-session decrease in avoidance responding. The 
VEH group maintained a high level of avoidance re-
sponding throughout this phase. Repeated-measures 
ANOVA showed a significant main effect of group, 
[F(3, 49) = 59.48, P < 0.001] and session [F(4, 196) = 9.46, 
P < 0.001], but no significant group × session interac-
tion [F(12, 196) = 1.44, NS]. Post-hoc tests revealed that 
all three OLZ groups were significantly different from 
the VEH group (all P < 0.001). In addition, the OLZ 0.5 
group differed significantly from the OLZ 1.0 and OLZ 
2.0 groups (P < 0.05). 
Olanzapine sensitization did not transfer to the phency-
clidine hyperlocomotion model 
Figure 2b shows the mean motor activity of the eight 
groups of rats during the 60-min test period after sa-
line or PCP injection. One-way ANOVA revealed a sig-
nificant main effect of group [F(7, 49) = 3.41, P < 0.005]. 
Posthoc tests showed that in comparison with the VEH-
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Figure 1. (a) Effect of repeated haloperidol treatment (0.03, 0.05, and 0.10 mg/kg, subcutaneously, – 60 min) on conditioned avoidance re-
sponding. Number of avoidance responses made by the rats in the four groups during the five drug conditioning sessions are expressed as 
mean ± standard error of the mean. * P < 0.05 relative to the vehicle (VEH) group. # P < 0.05 relative to the haloperidol (HAL) 0.05 and 1.0 
mg/kg groups. (b) Effect of acute haloperidol challenges on phencyclidine-induced hyperlocomotion. Motor activity data are expressed as the 
mean number of photobeam breaks. Rats were tested for 60 min after phencyclidine (PCP; 1.6 mg/kg, subcutaneously) injection. * P < 0.05 rel-
ative to the VEH+PCP group. (c) Effect of an acute haloperidol challenge (0.03 mg/kg, subcutaneously, – 60 min) on avoidance responding in 
rats that were previously treated with haloperidol (0.03, 0.05, and 0.10 mg/kg) or VEH during the sensitization induction phase. The avoidance 
data on the CS-only and retraining sessions are also presented for comparison. * P < 0.05 relative to the VEH group. # P < 0.05 relative to the 
HAL 0.1 mg/kg group. CS, conditioned stimulus.   
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Figure 2. (a) Effect of repeated olanzapine (OLZ) treatment (0.5, 1.0, and 2.0 mg/kg, subcutaneously, – 60 min) on conditioned avoidance re-
sponding. Number of avoidance responses made by the rats in the four groups during the five drug conditioning sessions are expressed as 
mean ± standard error of the mean. * P < 0.05 relative to the vehicle (VEH) group. # P < 0.05 relative to the OLZ 1.0 and 2.0 mg/kg groups. 
(b) Effect of acute OLZ challenges on phencyclidine (PCP)-induced hyperlocomotion. Motor activity data are expressed as the mean number 
of photobeam breaks. Rats were tested for 60 min after PCP (1.6 mg/kg, subcutaneously) injection. * P < 0.05 relative to the VEH+PCP group. 
(c) Effect of acute OLZ challenge (0.5 mg/kg, subcutaneously, – 60 min) on avoidance responding in rats that were previously treated with 
OLZ (0.5, 1.0, and 2.0 mg/kg) or VEH during the sensitization induction phase. The avoidance data on the conditioned stimulus-only and re-
training sessions are also presented for comparison. * P < 0.05 relative to the VEH group. # P < 0.05 relative to the OLZ 0.5 mg/kg group. CS, 
conditioned stimulus.   
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VEH + VEH group, the VEH-VEH + PCP group had a 
significantly higher motor activity (P < 0.01). This PCP ef-
fect was attenuated by OLZ pretreatment. In comparison 
with the VEH-VEH + PCP group, VEH-OLZ 2.0 + PCP, P 
= 0.004, and OLZ 2.0-OLZ 2.0 + PCP, P < 0.02, had signif-
icantly lower motor activity. More importantly, when the 
pairs of acute and repeated HAL groups were compared 
(e.g. VEH-OLZ 0.5 + PCP vs. OLZ 0.5-OLZ 0.5 + PCP), no 
significant difference was found.  
Olanzapine sensitization was detected in the conditioned 
avoidance response model and showed a dose-dependent 
function 
Figure 2c shows the number of avoidance responses dur-
ing the CS-only, retraining, and sensitization reassess-
ment sessions in the CAR. On the CS-only and retraining 
days, no significant group difference was found, CS-only 
[F(3, 49) = 2.51, P = 0.07], retraining: [F(3, 52) = 1.44, NS). 
In the sensitization reassessment test, all rats were tested 
under OLZ 0.5. One-way ANOVA showed a significant 
effect of group [F(3, 49) = 10.04, P <  0.001). Post-hoc tests 
showed that the OLZ 1.0 and OLZ 2.0 groups, but not 
the OLZ 0.5 group, had significantly fewer avoidances 
than the VEH group (P < 0.002, P < 0.001, and NS, re-
spectively). The OLZ 0.5 group also differed significantly 
from the other two OLZ groups (P < 0.05 vs. OLZ 1.0 and 
P < 0.02 vs. OLZ 2.0). 
Experiment 3: transferability of haloperidol-induced 
sensitization from the phencyclidine hyperlocomotion 
model to the conditioned avoidance response model 
Repeated haloperidol treatment produced a progres-
sively enhanced inhibition of phencyclidine-induced 
hyperlocomotion 
Figure 3a shows the mean motor activity of rats that re-
ceived HAL 0.05 or VEH treatment during the 60-min 
daily testing period after PCP injection. Haloperidol treat-
ment progressively enhanced its inhibition of PCP-in-
duced increase in motor activity across the 5 test days. 
Repeated-measures ANOVA showed significant main ef-
fects of group [F(1, 23) = 71.27, P < 0.001) and session [F(4, 
92) = 8.18, P < 0.001], and a significant group × session in-
teraction [F(4, 92) = 7.40, P < 0.001). 
Haloperidol sensitization did not transfer to the condi-
tioned avoidance response model 
Figure 3b shows the number of avoidance responses on 
the last (day 10) training day, the retraining day, and the 
sensitization assessment day (challenge test). All groups 
had a high level of avoidance response on the 10th train-
ing session [F(2, 22) = 0.11, NS] and on the retraining day 
[F(2, 22) = 1.48, NS], whereas in the challenge test, the 
two HAL groups had significantly lower avoidance levels 
than the VEH group. One-way ANOVA revealed a sig-
nificant main effect of group, [F(2, 22) = 9.93, P < 0.001). 
Post-hoc Tukey tests showed that both  HAL groups dif-
fered significantly from the VEH-VEH group (P < 0.01). 
More importantly, there was no significant difference be-
tween the two HAL groups, suggesting that prior HAL 
experience in the PCP model did not enhance the behav-
ioral effect of HAL in the CAR model. 
Haloperidol sensitization was present in the phencyclidine 
hyperlocomotion model 
Figure 3c shows the mean motor activity 30 min before 
and 60 min after PCP injection during the sensitization re-
assessment test. All rats received a first injection of HAL 
0.03, followed by PCP 3.2. In comparison with the VEH 
rats that received HAL for the first time in this model, 
rats that had previously received HAL 0.05 (Figure 3a) 
exhibited significantly lower motor activity in the first 30 
min [t(23) = - 2.92, P = 0.01], and the second 60 min [t(23) 
= –3.21, P = 0.005]. 
Experiment 4: transferability of olanzapine-induced 
sensitization from the phencyclidine hyperlocomotion 
model to the conditioned avoidance response model 
Repeated olanzapine treatment produced a progres-
sively enhanced inhibition of phencyclidine-induced 
hyperlocomotion 
Figure 4a shows the mean motor activity of rats that re-
ceived olanzapine 1.0 or VEH treatment during the 60-
min daily testing period after PCP injection. Olanzapine 
treatment progressively enhanced its inhibition of PCP-
induced increase of motor activity across the 5 test days. 
Repeated-measures ANOVA showed significant main 
effects of group [F(1, 24) = 40.65, P < 0.001) and session 
[F(4,96) = 3.18, P < 0.02], and a significant group × session 
interaction [F(4, 96) = 9.06, P < 0.001).  
Olanzapine sensitization did not transfer in the condi-
tioned avoidance response model 
Figure 4b shows the number of avoidance responses on 
the last (day 10) training day, retraining day, and on 
the sensitization assessment day (challenge test). All 
groups had a high level of avoidance response on the 
10th training session [F(2, 23) = 0.558, NS] and on the 
retraining day [F(2, 23) = 0.44 NS], whereas in the chal-
lenge test, the two OLZ groups had lower avoidance 
levels than the VEH group. One-way ANOVA revealed 
a significant main effect of group [F(2, 23) = 4.24, P < 
0.05]. Post-hoc Tukey tests showed that the OLZ 1.0-0.5 
group differed significantly from the VEH-VEH group 
(P = 0.026). Acute OLZ 0.5 decreased the avoidance re-
sponse, but the effect did not reach a significant level. 
Most importantly, there was no significant difference 
between the two OLZ groups, suggesting that prior 
OLZ experience in the PCP model did not enhance the 
behavioral effect of OLZ in the CAR model. However, 
the finding that only the OLZ 1.0-0.5 group, but not the 
VEH-OLZ 0.5 group, differed significantly from the 
VEH-VEH group indicates that there might be some re-
sidual effect of OLZ experience, which requires further 
verification.  
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Olanzapine sensitization was present in the phencyclidine 
hyperlocomotion model 
Figure 4c shows the mean motor activity in the 30 min 
before and 60 min after PCP injection during the sen-
sitization reassessment test. All rats received a first in-
jection of OLZ 0.5, followed by PCP 3.2. In comparison 
with the VEH rats that received olanzapine for the first 
time in this model, rats that had previously received 
OLZ 1.0 (Figure 4a) exhibited significantly lower motor 
activity in the first 30 min [t(24) = –3.19, P < 0.005], and 
significantly lower motor activity in the second 60 min 
[t(24) = –3.71, P < 0.001].   
Discussion
Our findings on antipsychotic sensitization induced 
by HAL and OLZ in both CAR and PCP hyperlocomo-
tion models are consistent with our previous studies, in 
which we showed that repeated HAL and OLZ treatment 
Figure 3. (a) Effect of repeated haloperidol treatment (0.05 mg/kg, subcutaneously) on phencyclidine (PCP)-induced hyperlocomotion. Mo-
tor activity data are expressed as the number of photobeam breaks. Rats were tested for 60 min after PCP (3.2 mg/kg, subcutaneously) injec-
tion. * P < 0.05 relative to the vehicle (VEH)+PCP group. (b) Number of avoidance responses made by the rats in the three groups during the 
10th training, retraining, and CS-only test sessions (under an acute haloperidol challenge, 0.03 mg/kg, subcutaneously, – 60 min) are expressed 
as mean ± standard error of the mean. * P < 0.05 relative to the VEH group. (c) Effect of acute haloperidol challenge (0.03 mg/kg, subcutane-
ously) on PCP-induced hyperlocomotion during the sensitization reassessment test. Motor activity data are expressed as the number of photo 
beam breaks. Rats were tested for 30 min (T30) before and 60 min (T60) after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 relative to 
the VEH group. CS, conditioned stimulus.    
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caused a progressive and persistent increase in their ef-
fects on avoidance responding and PCP-induced hyperlo-
comotion (Li et al., 2004b, 2007, 2009a, 2009b, 2010; Mead 
and Li, 2010). One unique aspect of this study is that two 
distinct animal models of antipsychotic drugs were uti-
lized to examine the phenomenon of antipsychotic sen-
sitization and its contextual and behavioral controls. The 
lack of transfer of sensitization was found in both direc-
tions and with both drugs, suggesting that it is a general 
feature of antipsychotic action, rather than an artifact of 
any specific models or drugs. 
The present study extended our work in the following 
four directions. First, it showed that antipsychotic sensi-
tization in the PCP hyperlocomotion model could also be 
assessed in the same way as in the CAR model, which is 
also the typical setup used to assess psychomotor  sen-
sitization (Anagnostaras and Robinson, 1996; Pierce and 
Kalivas, 1997; Robinson et al., 1998). That is, the expres-
Figure 4. (a) Effect of repeated olanzapine (OLZ) treatment (1.0 mg/kg, subcutaneously) on phencyclidine (PCP)-induced hyperlocomotion. 
Motor activity data are expressed as number of photobeam breaks. Rats were tested for 60 min after PCP (3.2 mg/kg, subcutaneously) injec-
tion. * P < 0.05 relative to the vehicle (VEH)+PCP group. (b) Number of avoidance responses made by the rats in the three groups during the 
10th training, retraining, and conditioned stimulus-only test sessions (under an acute olanzapine challenge, 0.5 mg/kg, subcutaneously, – 60 min) 
are expressed as mean ± standard error of the mean. * P < 0.05 relative to the VEH group. (c) Effect of acute OLZ challenge (0.5 mg/kg, sub-
cutaneously) on PCP-induced hyperlocomotion during the sensitization reassessment test. Motor activity data are expressed as number of 
photo beam breaks. Rats were tested for 30 min (T30) before and 60 min (T60) after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 rel-
ative to the VEH group.   
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sion of antipsychotic sensitization could be examined in 
a later challenge test during which all subjects are tested 
under the same antipsychotic drug treatment. The behav-
ioral sensitization is indicated by the higher inhibition in 
the antipsychotic experienced group than in the drug-na-
ive group. In our previous studies, antipsychotic-induced 
sensitization was only indicated by the progressively en-
hanced inhibition of PCP-induced hyperlocomotion dur-
ing the repeated drug-treatment period (Sun el al., 2009). 
The commonality among these different types of sensiti-
zation (e.g. psychomotor sensitization and antipsychotic 
sensitization) implies that many research techniques, ap-
proaches, and knowledge derived from psychomotor sen-
sitization studies might be introduced into the study of 
antipsychotic sensitization. 
Second, the study provided a novel approach to as-
sess the situational specificity of antipsychotic sensiti-
zation. Studies on contextual and behavioral controls of 
psychomotor sensitization or tolerance typically com-
pare a “paired” group (a group that receives drug injec-
tion in the test environment) with an “unpaired” group 
(a group that receives VEH injection in the test envi-
ronment, and drug in the home cage) in a single model 
(Poulos and Hinson, 1982; Amtage and Schmidt, 2003). 
The situational specificity of psychomotor sensitization 
is indicated by the finding that it is expressed only in the 
“paired” group but not in the “unpaired” group (Rob-
inson et al., 1998). Our previous work used a similar ap-
proach and demonstrated that within the CAR model, 
antipsychotic sensitization was indeed context depen-
dent (Li et al., 2009a). We found that rats that received 
HAL (0.05 mg/kg) or OLZ (1.0 mg/kg) and tested for 
avoidance (i.e., the “paired” group) exhibited a progres-
sive enhanced decrease in avoidance responding, indic-
ative of the antipsychotic sensitization effect, whereas 
rats that received these drugs in their home cages but 
tested for avoidance under VEH (i.e., the “unpaired” 
group) did not. The present study suggested that it is 
useful to use two different behavioral models to assess 
the situational specificity of antipsychotic sensitization. 
In comparison with the traditional one-model approach, 
this two-model approach is advantageous in revealing 
multiple sources of controls of antipsychotic sensitiza-
tion. Besides distinctive contextual cues, topographically 
different behavioral response patterns (i.e., avoidance 
response to a sound and PCP-induced increase in mo-
tor activity) certainly play a role in this process (Ohmori 
et al., 2000). This may explain the rather robust and com-
plete situational control of antipsychotic sensitization 
in this study. However, one limitation of this approach 
is its inability to determine the relative contributions of 
contextual cues and behavioral responses toward the de-
velopment and expression of antipsychotic sensitization. 
Future work utilizing both approaches is needed to ad-
dress this question. 
Third, the study extended the context-dependent sen-
sitization phenomenon involving antipsychotics from 
HAL-induced catalepsy (Lanis and Schmidt, 2001; Am-
tage and Schmidt, 2003; Klein and Schmidt, 2003) to sub-
ject behavioral responses relevant to human psychosis 
and to other antipsychotic drugs. Amtage and Schmidt 
(2003) and Klein and Schmidt (2003) have reported that 
intermittent HAL treatment and repeated catalepsy test-
ing caused an intensification of catalepsy over time and 
this intensification was completely context specific, as 
context changes abolished catalepsy sensitization. In the 
present study, we demonstrated that sensitization in-
duced by the atypical drug OLZ in the CAR and PCP hy-
perlocomotion models was also highly situation specific, 
suggesting that this feature of antipsychotic sensitization 
may cut across different groups of antipsychotic drugs 
and may be a universal feature reflecting the therapeutic 
effects of antipsychotic drugs. 
Finally, this study called attention to the issue of pos-
sible connections among various animal models of anti-
psychotic drug action. In preclinical psychopharmacol-
ogy, there are many diverse groups of animal models 
of antipsychotic activity, such as prepulse inhibition of 
acoustic startle, latent inhibition, amphetamine-induced 
and PCP-induced hyperlocomotion, the paw test, and so 
on (Weiner and Feldon, 1994; Kilts, 2001; Geyer and El-
lenbroek, 2003). Often, these models are utilized inde-
pendently without much attention paid to their possible 
relationships. As they all claim to be able to detect anti-
psychotic activity, one important issue is how they are re-
lated and whether it is possible to use one model to cross-
validate another. The present study suggests a way to 
explore this issue. 
As the context-dependent feature of antipsychotic sen-
sitization resembles that found in psychomotor sensiti-
zation (Vezina et al., 1989; Stewart and Vezina, 1991; An-
agnostaras and Robinson, 1996; Browman et al., 1998; 
Robinson et al., 1998; Anagnostaras et al., 2002) and tol-
erance (Siegel, 1978; Poulos et al., 1981; Siegel et al., 2000), 
the conceptualization of antipsychotic sensitization and 
its situational specificity can gain insights from the theo-
retical accounts of behavioral sensitization and tolerance. 
On the basis of the present study, our previous work (Li 
et al., 2004b, 2007, 2009a, 2009b, 2010; Mead and Li, 2010) 
and the work of others (Stewart and Vezina, 1991; Anag-
nostaras et al., 2002), we propose that three psychological 
and neuronal processes may govern the induction and ex-
pression of antipsychotic sensitization and its contextual 
and behavioral controls. 
First, repeated antipsychotic treatment may induce 
an unconditioned and nonassociative enhancement of 
behavioral effects (i.e., sensitization) attributable to the 
direct pharmacological action of a drug. There is sub-
stantial evidence indicating that chronic antipsychotic 
treatment alters the neurochemical systems that mediate 
their  behavioral activating effects (Meltzer et al., 1989; 
Konradi and Heckers, 2001; Meltzer et al., 2003; Schmitt 
et al., 2003; Lieberman et al., 2008). Many antipsychotic 
sensitization-related brain changes have been identified 
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and they are observed in the absence of any associative 
influence. For example, it has been shown that repeated 
antipsychotic treatment changes the density and sensi-
tivity of dopamine D2 receptors (Seeman, 2000; Samaha 
et al., 2007, 2008), 5-HT2A and 5-HT2C receptors (Buck-
land et al., 1997) and other receptors (McCoy et al., 1996; 
Marcus et al., 1997; Nudmamud and Reynolds, 2001; 
Tooney et al., 2005). Our own work on the neurochem-
ical basis of the antipsychotic sensitization induction in 
the CAR model also indicates a role for dopamine and 
serotonin receptors in this process (Li et al., 2010, 2011b). 
We found that with 2,5-dimethoxy-4-iodo-amphet-
amine, a selective 5-HT2A/2C serotonergic receptor ago-
nist, but not quinpirole, a selective D2/D3 dopaminergic 
receptor agonist, attenuated HAL sensitization of avoid-
ance responding, whereas pretreatment with quinpirole, 
but not 2,5-dimethoxy-4-iodo-amphetamine, attenuated 
the effect of OLZ. These findings suggest that the induc-
tion of HAL sensitization may be mediated by 5-HT2A/2C 
blockade-initiated neuroplasticity, whereas the induc-
tion of OLZ sensitization may be mediated by D2/D3 
blockade-initiated neuroplasticity. Psychologically, our 
previous work suggests that antipsychotic drugs dis-
rupt avoidance responding by progressively attenuat-
ing the motivational salience of the CS (Li et al., 2007). 
This hypothesis can also be utilized to explain the sen-
sitization effect in the PCP hyperlocomotion model. The 
PCP model can be thought of as reflecting an exagger-
ated exploration of the environment as a consequence 
of the increased motivational salience of environmen-
tal stimuli (Wise and Bozarth, 1987). Therefore, the anti-
psychotic-induced progressively enhanced inhibition of 
PCP-induced hyperlocomotion can be considered a con-
sequence of the weakened motivational salience of envi-
ronmental stimuli by antipsychotic treatment. 
Second, distinct contextual cues (e.g. environmental 
stimuli, interoceptive drug cue, etc.) and altered behav-
ioral responses in each model may develop an associa-
tion with unconditional drug effects through a Pavlov-
ian conditioning process, and thus become excitatory 
conditional stimuli. These contextual cues and behav-
ioral variables acquire the ability to elicit an antipsy-
chotic-like effect by themselves and may potentiate the 
sensitized response in an expected situation. The lack of 
transfer of sensitization between models could be attrib-
uted to the disruption of the excitatory controls of con-
textual cues and behaviors, as the across-model transfer 
entails changes not only in context but also in behav-
ioral responses. Contextual changes may consist of stim-
ulus addition (inclusion of novel contextual stimuli) as 
well as stimulus subtraction (loss of originally trained 
context). Substantial evidence suggests that contextual 
cues, especially the environmental stimuli and intero-
ceptive drug state, can serve as conditional stimuli and 
become associated with unconditional drug effects (as 
US) by a Pavlovian conditioning process after being re-
peatedly paired with a drug (Siegel et al., 2000). In our 
own lab, we have shown that rats that had been repeat-
edly treated with HAL (0.05 mg/kg, subcutaneously) 
and clozapine (20 mg/kg, subcutaneously) during the 
acquisition or the extinction phase of the CAR model 
still showed a decreased avoidance response when they 
were tested 2 days later in the absence of the drug (Li et 
al., 2004b). In the present study, we also observed that 
rats previously treated with HAL (0.03 and 0.05 mg/kg) 
made fewer avoidance responses on the CS-only drug-
free test. These findings imply that the CAR testing en-
vironment exerted an antipsychotic-like effect on avoid-
ance responding. Future work is needed to specify the 
magnitude of the impact of contextual cues on antipsy-
chotic sensitization. 
Finally, contextual stimuli and different topographic 
behavioral responses may serve as occasion setters to 
modulate the manifestation of sensitized responses. Oc-
casion setters are a class of conditional stimuli that do 
not themselves elicit an antipsychotic-like effect, but 
modulate the ability of other stimuli to elicit responses 
(Holland, 1989). A change of testing models may cause 
a disruption of the occasion-setting property of contex-
tual stimuli and behavioral responses, which leads to 
the disruption of across-model transfer of antipsychotic 
sensitization. It is well documented that contextual cues 
and altered behavioral responses can function as occa-
sion setters to modulate the expression of psychomotor 
sensitization involving psychostimulants (Smith, 1991; 
Anagnostaras and Robinson, 1996; Lanis and Schmidt, 
2001; Sripada et al., 2001). Our previous work also pro-
vides evidence supporting this account. For example, in 
the study by Mead and Li (2010), we showed that rats in-
termittently treated with OLZ (1.0 mg/kg, subcutane-
ously) or HAL (0.03 mg/kg, subcutaneously) on the first 
day of a 3-day cycle for seven cycles exhibited a progres-
sive across-session decline in avoidance responding (i.e., 
antipsychotic sensitization), despite the fact that they ex-
hibited a comparable high level of avoidance responding 
on the third day of each cycle during the drug-free re-
training session. As we have previously discussed (Mead 
and Li, 2010), an antipsychotic drug and altered behav-
ioral responses can act as an occasion setter (Maes and 
Vossen, 1997), which sets the condition in which rats be-
have on the basis of their previous drug experience in 
the avoidance testing context, or it may directly imprint 
the brain to create a drug “memory trace” about avoid-
ance responding under drug (the neural basis of antipsy-
chotic sensitization). One prediction on the basis of this 
drug-dependent sensitization mechanism is that even if 
the drug has been stopped and the avoidance respond-
ing has fully reverted to the predrug level, during the 
next exposure to antipsychotic treatment, the subjects 
with a previous drug experience should show a greater 
response, a  prediction that was confirmed for both OLZ 
and risperidone (Mead and Li, 2010). 
In summary, the present study used a novel two-
model approach and provided strong evidence for the 
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contextual and behavioral controls of antipsychotic sen-
sitization. Our work also revealed three neuropsycho-
logical processes that are potentially critical for the in-
duction and expression of antipsychotic sensitization, 
emphasizing the long-term neuroplasticities due to 
chronic drug treatment and the role of contextual cues 
and behaviors functioning as conditional stimuli and 
occasion setters. Insofar as this effect is important for 
maintaining antipsychotic effects over time, understand-
ing the neurobiological and psychological mechanisms 
behind it would greatly enhance our knowledge of the 
psychological and neurochemical nature of antipsy-
chotic treatment in the clinic. 
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